Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimizing management of stage IV EGFR mutant non-small cell lung cancer in Asia: An expert opinion.

International journal of cancer - 15 Oct 2025

Chang Gee-Chen, Kapoor Akhil, Lee Chee Khoon, Su Chunxia, Chan Daniel, Ladrera Guia Elena Imelda, Kim Hye Ryun, Sumon Mostafa Aziz, Suryavanshi Moushumi, Andarini Sita, Yoshida Tatsuya, Reungwetwattana Thanyanan, Nguyen Tuan Khoi, Voon Pei Jye

Abstract excerpt

Lung cancer is Asia's most prevalent cancer, accounting for the highest global patient share. A significant number of non-small cell lung cancer (NSCLC) patients in Asia exhibit mutations in the epidermal growth factor receptor (EGFR). Although clinical outcomes are improving with newer therapies, challenges persist in the effective management of EGFR mutant (EGFRm) NSCLC. Given the substantial disease burden,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Asia

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to High-Throughput Nucleotide Sequencing

Share to Lung Neoplasms

Share to Neoplasm Staging

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 40515576
DOI: 10.1002/ijc.35512
PMCID: PMC12375841

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimizing management of stage IV EGFR mutant non‐small cell lung cancer in Asia: An expert opinionPMID 40515576Read ↗

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.Semantic proximity Read ↗

The treatment of advanced lung adenocarcinoma with activating EGFR mutations.Semantic proximity Read ↗

Recent Advances in the Management of EGFR Mutated Advanced Non-Small Cell Lung Cancer-A Narrative ReviewSemantic proximity Read ↗

Targeted Therapy for Patients With Metastatic Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Somatic gene mutations and their association with treatment outcomes among Indo-Asian Lung Cancer patients.Semantic proximity Read ↗

EGFR mutation testing, treatment and survival in stage I-III non-small cell lung cancer: CancerLinQ Discovery database retrospective analysis.Semantic proximity Read ↗

Emerging paradigms in targeted treatments for Asian patients with NSCLC.Semantic proximity Read ↗

Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations.Semantic proximity Read ↗

Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis.Semantic proximity Read ↗

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.Semantic proximity Read ↗

Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary managementSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.